Emily Drabant Conley is currently the CEO of Nuvalent, Inc., a biotech company focused on developing innovative treatments. She brings a wealth of experience from her previous roles, including serving as the CEO of Federation Bio, where she led projects...
Emily Drabant Conley is currently the CEO of Nuvalent, Inc., a biotech company focused on developing innovative treatments. She brings a wealth of experience from her previous roles, including serving as the CEO of Federation Bio, where she led projects in microbial cell therapies across various diseases. Emily also worked for over a decade at 23andMe, a company recognized for personal genomics. In her current role, she has achieved significant results, with her performance goals exceeding expectations in 2023, earning her a bonus that reflects her impact on the company's direction. She joined Nuvalent’s board of directors in February 2022 and was appointed CEO later that year. Emily holds an M.B.A. and has been acknowledged in several influential lists, showcasing her prominence in the biotech industry. Her decisions at Nuvalent are backed by a strong focus on research and development, aligning strategic goals with company success, making her a key player in advancing biotechnology.